Ex-OpenAI Science Chief Kevin Weil Launches Warp Sciences With $215 Million

The gap between digital AI models and physical biology is closing with $215 million in new capital. Kevin Weil, the former head of science at OpenAI, has launched Warp Sciences, a company built to automate the manual processes of wet-lab research. The funding round signals a major bet on replacing human hands with robotic systems in drug discovery.[1][2]

Warp Sciences is targeting the bottleneck that slows down pharmaceutical development: the physical execution of experiments. While AI can generate millions of potential drug candidates in seconds, testing those compounds still requires scientists to manually mix liquids, culture cells, and run assays in physical laboratories. Weil's new venture aims to build robotic systems that execute these tests autonomously.[2][5]

The startup's approach combines hardware and software to create what it calls "closed-loop" discovery. In this model, an AI system designs an experiment, robotic arms execute it in a wet lab, and the results are fed directly back into the model to inform the next iteration. This continuous cycle is designed to operate 24 hours a day without human intervention.[2]

"We are building the physical infrastructure that biology needs to keep pace with artificial intelligence," Weil said in a statement announcing the launch. "The models are ready, but the labs are not. Warp Sciences will bridge that divide by turning wet labs into programmable environments."[1][2]

The Cost of Physical Automation

The $215 million launch capital provides Warp Sciences with the resources to build its initial robotic facilities and hire a team of biologists, hardware engineers, and machine learning researchers. The size of the round reflects the high capital requirements of building physical laboratory infrastructure, which is significantly more expensive than developing software alone.[1][4]

Weil's departure from OpenAI to found Warp Sciences highlights a broader migration of AI talent toward the life sciences. During his tenure at OpenAI, Weil oversaw the development of scientific applications for the company's large language models. His move suggests that the next frontier for AI is not just generating text or code, but directly manipulating the physical world to cure disease.[1][3]

The pharmaceutical industry has long struggled with the "Eroom's Law" trend, where the cost of developing a new drug doubles roughly every nine years, despite advances in technology. By automating the most labor-intensive parts of the discovery process, Warp Sciences aims to reverse this trend and dramatically reduce the time and cost required to bring new therapies to market.[5]

However, automating biology is notoriously difficult. Unlike the deterministic world of software, biological systems are messy, unpredictable, and highly sensitive to environmental conditions. Previous attempts to fully automate wet labs have often failed because robots struggle to handle the subtle variations in temperature, humidity, and cellular behavior that human scientists intuitively manage.[2][5]

Adapting to Biological Chaos

Warp Sciences plans to overcome these challenges by using advanced computer vision and reinforcement learning to train its robots. Instead of relying on rigid, pre-programmed scripts, the company's robotic systems are designed to adapt to unexpected changes in the lab environment, much like a human scientist would.[2]

The company's initial focus will be on automating high-throughput screening and cell culture maintenance, two of the most repetitive and time-consuming tasks in preclinical drug discovery. By proving its technology on these foundational processes, Warp Sciences hopes to build trust with pharmaceutical partners before tackling more complex experimental designs.[5]

The launch of Warp Sciences places it in competition with other tech-forward biology companies, such as Recursion Pharmaceuticals and Insitro, which are also building automated laboratories. However, Warp's pure focus on building the robotic infrastructure, rather than developing its own pipeline of drugs, positions it as a potential platform provider for the broader industry.[2][5]

The success of Warp Sciences will depend on its ability to prove that its robotic systems can produce data that is as reliable and reproducible as that generated by human scientists. If it can achieve this, the company could fundamentally change the economics of drug discovery, making it possible to test thousands of hypotheses simultaneously and accelerating the development of life-saving medicines.[1]